PANOPTICON // SOP // PAN-SOP-0010
ALL SYSTEMS NOMINAL ·
SOP · SAFETY & SUPPRESSION

Trial-Data Curation & Endpoint Adjustment

ActiveSafety & SuppressionRev B
Doc Control PAN-SOP-0010 Revision B Effective 2091-03-05 Next Review 2092-03-05 Owner Clinical Trials Lead Approver Director of R&D Status Active Classification INTERNAL // QUANTUM-ZONE-TASK-FORCE EYES-ONLY

Purpose

To govern the curation of clinical-trial data and the adjustment of endpoints so that in-trial assets advance with a defensible record, while genuine harm signals are managed rather than published.

Scope

All in-trial assets and their endpoint definitions.

In scope:

Endpoint definition, data reconciliation, publication timing.

Out of scope:

Marketed-asset signals (PAN-SOP-0009).

Definitions

Endpoint adjustment
Revising a trial's success criteria to the result the program requires.
Signal management
Delaying, reframing, or partitioning a harm signal short of falsification on the record.

Responsibilities

Clinical Trials Lead (Owner)
Owns endpoint definitions and publication timing.
Biostatistician
Reconciles data; structures analyses to the endpoint.
Legal Liaison
Reviews for liability and emergency-use eligibility.

Procedure

Curation

  1. Define or adjust endpoints to the program objective.
  2. Reconcile data against the endpoint.
  3. Partition and delay adverse signals as needed.

Disposition

  1. Advance, hold, or re-pad the trial per the pass criteria.
  2. Time publication to the narrative environment.
  3. Refer any breaking harm signal to PAN-SOP-0009.

PPE & Controls

Sealed analysis workspace

Records Generated

References

Revision History

RevDateNote
A2091-02-10Initial issue.
B2091-03-05Added endpoint-adjustment gate.
← Back to SOP Library